Profile of minocycline and its potential in the treatment of schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1103-1111

  Zhang, Lulu ^a,b   Zhao, Jingping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Microglia; Minocycline; Neuroinflammation; Schizophrenia

Indexed keywords

HALOPERIDOL; MINOCYCLINE; OLANZAPINE; PLACEBO;

APOPTOSIS; ARTICLE; DISEASE MODEL; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; FOLLOW UP; HUMAN; MICROGLIA; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER;

EID: 84902578330     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S64236     Document Type: Article

References (113)

1. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: micro-glia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009; 63(3):257-265.
2. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71(9):1115-1124.
3. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429-447.
4. Essali A, Al Haj HN, Li C, Rathbone J. Clozapine versus typical neuro-leptic medication for schizophrenia. Cochrane Database Syst Rev. 2009; 1:CD000059.
5. Asenjo LC, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;11:CD006633.
6. Gilmour G, Dix S, Fellini L, et al. NMDA receptors, cognition and schizophrenia - testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology. 2012;62(3):1401-1412.
7. Terry AV, Jr. Role of the central cholinergic system in the therapeutics of schizophrenia. Curr Neuropharmacol. 2008;6(3):286-292.
8. Sander K, Kottke T, Stark H. Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull. 2008;31(12):2163-2181.
9. Meltzer HY. Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol. 2012;(212):87-124.
10. Ginovart N, Kapur S. Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol. 2012;212:27-52.
11. Mulle JG. Schizophrenia genetics: progress, at last. Curr Opin Genet Dev. 2012;22(3):238-244.
12. Gupta S, Kulhara P. What is schizophrenia: a neurodevelopmental or neurodegenerative disorder or a combination of both? A critical analysis. Indian J Psychiatry. 2010;52(1):21-27.
13. Rapoport JL, Giedd JN, Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry. 2012;17(12):1228-1238.
14. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychop-harmacol. 2011;14(7):997-1012.
15. Meyer U. Anti-inflammatory signaling in schizophrenia. Brain Behav Immun. 2011;25(8):1507-1518.
16. Monji A, Kato TA, Mizoguchi Y, et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsy-chopharmacol Biol Psychiatry. 2013;42(5):115-121.
17. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol. 2004;3(12):744-751.
18. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res. 2009;196(2):168-179.
19. Dean OM, Data-Franco J, Giorlando F, Berk M. Minocycline: therapeutic potential in psychiatry. CNS Drugs. 2012;26(5):391-401.
20. Keller WR, Kum LM, Wehring HJ, Koola MM, Buchanan RW, Kelly DL. A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol. 2013;27(4):337-342.
21. Levkovitz Y, Levi U, Braw Y, Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res. 2007;1154:154-162.
22. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010; 71(2):138-149.
23. Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefts negative symptoms in early schizophrenia: a randomized double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012;26(9):1185-1193.
24. Muller N, Myint AM, Schwarz MJ. Inflammation in schizophrenia. Adv Protein Chem Struct Biol. 2012;88:49-68.
25. Ashdown H, Dumont Y, Ng M, Poole S, Boksa P, Luheshi GN. The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. Mol Psychiatry. 2006;11(1):47-55.
26. Shen Q, Li ZQ, Sun Y, et al. The role of pro-inflammatory factors in mediating the effects on the fetus of prenatal undernutrition: implications for schizophrenia. Schizophr Res. 2008;99(1-3):48-55.
27. Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:20-34.
28. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry. 2007;62(7):711-721.
29. Narayan S, Tang B, Head SR, et al. Molecular profles of schizophrenia in the CNS at different stages of illness. Brain Res. 2008;1239: 235-248.
30. Bessis A, Bechade C, Bernard D, Roumier A. Microglial control of neuronal death and synaptic properties. Glia. 2007;55(3):233-238.
31. Steiner J, Bogerts B, Sarnyai Z, et al. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. World J Biol Psychiatry. 2012; 13(7):482-492.
32. Alliot F, Godin I, Pessac B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res Dev Brain Res. 1999;117(2):145-152.
33. Pont-Lezica L, Bechade C, Belarif-Cantaut Y, Pascual O, Bessis A. Physiological roles of microglia during development. J Neurochem. 2011;119(5):901-908.
34. Schlegelmilch T, Henke K, Peri F. Microglia in the developing brain: from immunity to behaviour. Curr Opin Neurobiol. 2011;21(1):5-10.
35. Tremblay ME, Majewska AK. A role for microglia in synaptic plasticity? Commun Integr Biol. 2011;4(2):220-222.
36. Tremblay ME, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A. The role of microglia in the healthy brain. J Neurosci. 2011;31(45): 16064-16069.
37. Nurun BN, Tanaka T, Kamino K, et al. Toll-like receptor 3 mediated hyperphosphorylation of tau in human SH-SY5Y neuroblastoma cells. Psychiatry Clin Neurosci. 2006;60 Suppl 1:S27-S33.
38. Block ML, Hong JS. Microglia and inflammation-mediated neurodegen-eration: multiple triggers with a common mechanism. Prog Neurobiol. 2005;76(2):77-98.
39. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 1999; 46(6):729-739.
40. Perez-Neri I, Ramirez-Bermudez J, Montes S, Rios C. Possible mechanisms of neurodegeneration in schizophrenia. Neurochem Res. 2006;31(10):1279-1294.
41. Nakki R, Koistinaho J, Sharp FR, Sagar SM. Cerebellar toxicity of phencyclidine. J Neurosci. 1995;15(3-2):2097-2108.
42. Nakki R, Nickolenko J, Chang J, Sagar SM, Sharp FR. Haloperidol prevents ketamine and phencyclidine-induced HSP70 protein expression but not microglial activation. Exp Neurol. 1996;137(2):234-241.
43. Steiner J, Mawrin C, Ziegeler A, et al. Distribution of HLA-DR-positive microglia in schizophrenia refects impaired cerebral lateralization. Acta Neuropathol. 2006;112(3):305-316.
44. Steiner J, Bielau H, Brisch R, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008; 42(2):151-157.
45. Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett. 1999;271(2):126-128.
46. Radewicz K, Garey LJ, Gentleman SM, Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol. 2000; 59(2):137-150.
47. Wierzba-Bobrowicz T, Lewandowska E, Lechowicz W, Stepień T, Pasennik E. Quantitative analysis of activated microglia, ramifed and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol. 2005;43(2):81-89.
48. Van Berckel BN, Bossong MG, Boellaard R, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008;64(9):820-822.
49. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med. 2009;50(11):1801-1807.
50. Takahashi N, Sakurai T. Roles of glial cells in schizophrenia: possible targets for therapeutic approaches. Neurobiol Dis. 2013;53:49-60.
51. Frick LR, Williams K, Pittenger C. Microglial dysregulation in psychiatric disease. Clin Dev Immunol. 2013;2013:608654.
52. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003;302(5651):1760-1765.
53. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A. 2003;100(23):13632-13637.
54. Cacci E, Claasen JH, Kokaia Z. Microglia-derived tumor necrosis factor-alpha exaggerates death of newborn hippocampal progenitor cells in vitro. J Neurosci Res. 2005;80(6):789-797.
55. Iosif RE, Ekdahl CT, Ahlenius H, et al. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci. 2006;26(38):9703-9712.
56. Kaneko N, Kudo K, Mabuchi T, et al. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology. 2006;31(12):2619-2626.
57. Muller N, Krause D, Dehning S, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res. 2010;121(1-3):118-124.
58. Muller N, Riedel M, Scheppach C, et al. Benefcial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159(6):1029-1034.
59. Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotec-tive in global brain ischemia. Proc Natl Acad Sci U S A. 1998; 95(26):15769-15774.
60. Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A. 1999;96(23):13496-13500.
61. Dommeguess MA, Plaisant F, Vermey C, Gressens P. Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection. Neuroscience. 2003;121(3):619-628.
62. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocy-cline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 2001;21(8):2580-2588.
63. Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM. Minocy-cline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol. 2002;52(1):54-61.
64. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000;6(7):797-801.
65. Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine mouse model of Parkinson disease. J Neurosci. 2002; 22(5):1763-1771.
66. Homsi S, Federico F, Croci N, et al. Minocycline effects on cerebral edema: relations with inflammatory and oxidative stress markers following traumatic brain injury in mice. Brain Res. 2009;1291:122-132.
67. Ahuja M, Bishnoi M, Chopra K. Protective effect of minocy-cline, a semi-synthetic second-generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity. Toxicology. 2008;244(2-3):111-122.
68. Garcia-Martinez EM, Sanz-Blasco S, Karachitos A, et al. Mitochondria and calcium fux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem Pharmacol. 2010;79(2):239-250.
69. Davis KL, Stewart DG, Friedman JI, et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry. 2003;60(5):443-456.
70. Kumra S, Ashtari M, Cervellione KL, et al. White matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging study. J Am Acad Child Adolesc Psychiatry. 2005;44(9):934-941.
71. Salisbury DF, Kuroki N, Kasai K, Shenton ME, McCarley R W. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry. 2007;64(5):521-529.
72. Hulshoff Pol HE, Kahn RS. What happens after the frst episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull. 2008;34(2):354-366.
73. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res. 2006;81(1):47-63.
74. Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuro-protection in Parkinson's disease. Ann Neurol. 1998;44(3 Suppl 1): S167-S174.
75. Medina S, Martinez M, Hernanz A. Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. Free Radic Res. 2002;36(11):1179-1184.
76. Buntinx M, Moreels M, Vandenabeele F, et al. Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosis. J Neurosci Res. 2004;76(6):834-845.
77. Thomas M, Le WD. Minocycline: neuroprotective mechanisms in Parkinson's disease. Curr Pharm Des. 2004;10(6):679-686.
78. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A. 2006;103(25):9685-9690.
79. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong V W. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain. 2002;125 Pt 6:1297-1308.
80. Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem. 2004;279(19):19948-19954.
81. Castanares M, Vera Y, Erkkila K, et al. Minocycline up-regulates BCL-2 levels in mitochondria and attenuates male germ cell apoptosis. Biochem Biophys Res Commun. 2005;337(2):663-669.
82. Scarabelli TM, Stephanou A, Pasini E, et al. Minocycline inhibits cas-pase activation and reactivation, increases the ratio of XIAP to SMAC/ DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J Am Coll Cardiol. 2004;43(5):865-874.
83. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000;6(7):797-801.
84. Teng YD, Choi H, Onario RC, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional defcits after spinal cord injury. Proc Natl Acad Sci U S A. 2004;101(9):3071-3076.
85. Yang D, Liu X, Zhang R, et al. Increased apoptosis and different regulation of pro-apoptosis protein bax and antiapoptosis protein bcl-2 in the olfactory bulb of a rat model of depression. Neurosci Lett. 2011;504(1):18-22.
86. Kernt M, Neubauer AS, Eibl KH, et al. Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2. Clin Ophthalmol. 2010;4:591-604.
87. Tang CM, Hwang CS, Chen SD, Yang DI. Neuroprotective mechanisms of minocycline against sphingomyelinase/ceramide toxicity: roles of Bcl-2 and thioredoxin. Free Radic Biol Med. 2011;50(6):710-721.
88. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cyto-chrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002;417(6884):74-78.
89. Wang X, Zhu S, Drozda M, et al. Minocycline inhibits caspase- independent and dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A. 2003;100(18): 10483-10487.
90. Fuks B, Talaga P, Huart C, et al. In vitro properties of 5-(benzylsulfonyl)-4-bromo-2- methyl- 3(2H)-pyridazinone: a novel permeability transition pore inhibitor. Eur J Pharmacol. 2005;519(1-2):24-30.
91. Leung AW, Halestrap AP. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim Biophys Acta. 2008;1777(7-8):946-952.
92. Morimoto N, Shimazawa M, Yamashima T, Nagai H, Hara H. Mino-cycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage. Brain Res. 2005;1044(1):8-15.
93. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger J W. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem. 2005;94(3):819-827.
94. Wiedholz LM, Owens WA, Horton RE, et al. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol Psychiatry. 2008;13(6):631-640.
95. Woolley ML, Waters KA, Gartlon JE, et al. Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat. Psychopharmacology (Berl). 2009;202(1-3):343-354.
96. Wang JQ, Arora A, Yang L, et al. Phosphorylation of AMPA receptors: mechanisms and synaptic plasticity. Mol Neurobiol. 2005; 32(3):237-249.
97. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopamin-ergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A. 2001;98(25):14669-14674.
98. Wasserman JK, Schlichter LC. Neuron death and inflammation in a rat model of intracerebral hemorrhage: effects of delayed minocycline treatment. Brain Res. 2007;1136(1):208-218.
99. Zhang L, Kitaichi K, Fujimoto Y, et al. Protective effects of minocy-cline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(8):1381-1393.
100. Levkovitz Y, Levi U, Braw Y, Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res. 2007;1154:154-162.
101. Monte AS, de Souza GC, McIntyre RS, et al. Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: possible involvement of antioxidant and nitrergic pathways. J Psychopharmacol. 2013;27(11):1032-1043.
102. Hashimoto K, Tsukada H, Nishiyama S, Fukumoto D, Kakiuchi T, Iyo M. Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a positron emission tomography study in conscious monkeys. Biol Psychiatry. 2007;61(5):577-581.
103. Zhang L, Shirayama Y, Iyo M, Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition defcits in mice after administration of the NMDA receptor antagonist dizocilpine. Neu-ropsychopharmacology. 2007;32(9):2004-2010.
104. Fujita Y, Ishima T, Kunitachi S, et al. Phencyclidine-induced cognitive defcits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):336-339.
105. Mizoguchi H, Takuma K, Fukakusa A, et al. Improvement by minocy-cline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl). 2008;196(2):233-241.
106. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(1):304-307.
107. Chaves C, de Marque CR, Wichert-Ana L, et al. Functional neuroim-aging of minocycline's effect in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(3):550-552.
108. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol. 2008;31(5):287-292.
109. Kelly DL, Vyas G, Richardson CM, et al. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res. 2011;133(1-3):257-258.
110. Jhamnani K, Shivakumar V, Kalmady S, Rao NP, Venkatasubramanian G. Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia. J Neuropsychiatry Clin Neurosci. 2013;25(1):E06-E07.
111. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71(2):138-149.
112. Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomized double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012;26(9):1185-1193.
113. Sofuoglu M, Mooney M, Kosten T, Waters A, Hashimoto K. Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans. Psychopharmacology (Berl). 2011;213(1):61-68.